Salix Pharmaceuticals Company Profile (NASDAQ:SLXP)

About Salix Pharmaceuticals

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Industry, Sector and Symbol:

Sector: Healthcare
Industry: Pharmaceuticals
Sub-Industry: Pharmaceuticals
Exchange: NASDAQ
Symbol: SLXP
CUSIP: 79543510

Key Metrics:

Previous Close: $169.00
50 Day Moving Average: $173
200 Day Moving Average: $133
Trailing P/E Ratio: N/A
Foreward P/E Ratio: 18.78
P/E Growth: 0
Market Cap: $N/A

Additional Links:

Companies Related to Salix Pharmaceuticals:

Consensus Ratings for Salix Pharmaceuticals (NASDAQ:SLXP) (?)

Ratings Breakdown:	No ratings tracked in the last 12 months.
Consensus Rating:	N/A (Score: NaN)
Consensus Price Target:	N/A

Analysts' Ratings History for Salix Pharmaceuticals (NASDAQ:SLXP)

Show:

Date	Firm	Action	Rating	Price Target
3/18/2015	Jefferies Group	Downgrade	Buy -> Hold	$149.00 -> $173.00
3/16/2015	Mizuho	Boost Price Target	Neutral	$158.00 -> $173.00
2/24/2015	Cantor Fitzgerald	Downgrade	Buy -> Hold	$151.00 -> $158.00
2/23/2015	Leerink Swann	Downgrade	Outperform -> Market Perform
2/23/2015	Piper Jaffray Cos.	Downgrade	Overweight -> Neutral	$160.00 -> $158.00
2/12/2015	Sterne Agee CRT	Downgrade	Buy -> Neutral
12/18/2014	Deutsche Bank AG	Reiterated Rating	Hold	$107.00
12/18/2014	Goldman Sachs Group Inc.	Reiterated Rating	HOLD	$111.00
12/18/2014	Credit Suisse Group AG	Boost Price Target	Neutral	$111.00 -> $121.00
12/17/2014	Canaccord Genuity	Boost Price Target	Buy	$117.00 -> $147.00
11/7/2014	Roth Capital	Downgrade	Buy -> Neutral	$155.00 -> $95.00
11/7/2014	Stifel Nicolaus	Downgrade	Buy -> Hold	$185.00
11/7/2014	William Blair	Downgrade	Outperform -> Market Perform	$184.00 -> $89.00

(Data available from 9/26/2014 forward)

Earnings History for Salix Pharmaceuticals (NASDAQ:SLXP)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
3/2/2015	Q414	($0.29)	($2.61)	$187.97 million	$13.00 million	View	N/A
11/6/2014	Q314	$1.56	$1.53	$394.00 million	$354.70 million	View	N/A
8/7/2014	Q214	$1.69	$1.59	$397.06 million	$382.00 million	View	Listen
5/8/2014	Q114	$0.91	$1.05	$372.91 million	$384.00 million	View	Listen
2/27/2014	Q413	$0.93	$1.06	$247.29 million	$257.60 million	View	Listen
11/7/2013	Q313	$0.86	$0.89	$239.70 million	$238.20 million	View	N/A
8/8/2013	Q2 2013	$0.81	$0.87	$226.34 million	$235.40 million	View	Listen
5/9/2013	Q1 2013	$0.67	$0.63	$205.94 million	$202.60 million	View	Listen
2/28/2013	Q4 2012	$0.78	$0.81	$199.41 million	$198.17 million	View	N/A
11/7/2012	Q312	$0.69	$0.95	$187.23 million	$185.13 million	View	N/A
8/8/2012		$0.54	$0.79			View	N/A
5/7/2012		$0.56	$0.67			View	N/A
11/8/2011		$0.60	$0.77			View	N/A
8/8/2011		$0.44	$0.32			View	N/A
5/5/2011		$0.17	$0.34			View	N/A
2/28/2011		$0.49	$0.66			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Salix Pharmaceuticals (NASDAQ:SLXP)

Current Year EPS Consensus Estimate: $4 EPS
Next Year EPS Consensus Estimate: $9 EPS

Dividend History for Salix Pharmaceuticals (NASDAQ:SLXP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Salix Pharmaceuticals (NASDAQ:SLXP)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
3/6/2015	Timothy J Creech	Insider	Sell	4,600	$157.67	$725,282.00
3/6/2015	William P Forbes	EVP	Sell	20,000	$157.96	$3,159,200.00
11/12/2014	William P Forbes	EVP	Sell	11,079	$95.05	$1,053,058.95
6/26/2014	Carolyn J Logan	CEO	Sell	53,057	$123.38	$6,546,172.66
4/22/2014	Alonzo Thomas D	Director	Sell	11,530	$110.89	$1,278,561.70
1/10/2014	Alonzo Thomas D	Director	Sell	12,050	$91.83	$1,106,551.50
1/9/2014	Adam Derbyshire	CFO	Sell	30,001	$91.48	$2,744,491.48
1/8/2014	William Forbes	EVP	Sell	8,000	$90.06	$720,480.00
1/7/2014	Rick Scruggs	EVP	Sell	8,463	$88.31	$747,367.53
1/7/2014	William Keane	Director	Sell	22,500	$88.31	$1,986,975.00
7/24/2013	William P Forbes	EVP	Sell	12,000	$70.93	$851,160.00
4/10/2013	William P Forbes	EVP	Sell	8,673	$49.37	$428,186.01
12/26/2012	Adam C Derbyshire	CFO	Sell	60,000	$41.44	$2,486,400.00
11/13/2012	Mark A Sirgo	Director	Sell	3,450	$40.53	$139,828.50

(Data available from 1/1/2013 forward)

Latest Headlines for Salix Pharmaceuticals (NASDAQ:SLXP)

Date	Headline
	Valeant’s Strategies for Its Dermatology, Gastroenterology Drugs (NASDAQ:SLXP) marketrealist.com - September 20 at 12:07 PM
	Valeant Stock: Many Are Bullish on Valeant Pharmaceuticals Intl Inc - Profit Confidential (NASDAQ:SLXP) www.profitconfidential.com - September 19 at 11:55 AM
	Valeant: Are the Salix and Dermatology Portfolios Recovering? (NASDAQ:SLXP) marketrealist.com - September 14 at 11:43 AM
	New Broker Ratings For Salix Pharmaceuticals, Ltd. (NASDAQ ... - FTSE News (NASDAQ:SLXP) www.ftsenews.co.uk - July 26 at 10:51 AM
	Valeant gets new approval for legacy Salix drug (NASDAQ:SLXP) www.bizjournals.com - July 20 at 1:50 PM
	Valeant's Drug Approvals May Save the Day (NASDAQ:SLXP) www.thestreet.com - July 20 at 12:30 PM
	Valeant Scores 'Vindicating Win' as 2 Key Drugs Clear FDA Hurdles (NASDAQ:SLXP) realmoney.thestreet.com - July 20 at 9:21 AM
	Next Weeks Broker Price Targets For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Fiscal Standard (NASDAQ:SLXP) www.fiscalstandard.com - July 17 at 11:30 AM
	Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Updated Price Targets - FTSE News (NASDAQ:SLXP) www.ftsenews.co.uk - June 28 at 7:19 PM
	Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Current Analyst Ratings - Fiscal Standard (NASDAQ:SLXP) www.fiscalstandard.com - June 24 at 7:32 PM
	How Much Is Valeant Pharmaceuticals Really Worth? (NASDAQ:SLXP) www.fool.com - June 17 at 2:41 PM
	Pfizer Drug Prices Rise By 8.8% Average - PharmaLive (press release) (subscription) (NASDAQ:SLXP) www.pharmalive.com - June 11 at 10:25 AM
	Doctors Who Prescribed Salix Drugs Ate Well (NASDAQ:SLXP) www.bloomberg.com - June 10 at 3:43 PM
	Details of kickbacks and fraud emerge in Valeant's Salix unit settlement (NASDAQ:SLXP) www.bizjournals.com - June 10 at 11:55 AM
	Valeant (VRX) Stock Slides on $54 Million Settlement (NASDAQ:SLXP) www.thestreet.com - June 10 at 8:56 AM
	Valeant pays $54 million to settle U.S. kickback, fraud claims (NASDAQ:SLXP) finance.yahoo.com - June 9 at 5:45 PM
	Valeant pays $54 mln to settle U.S. kickback, fraud claims (NASDAQ:SLXP) finance.yahoo.com - June 9 at 5:43 PM
	Valeant Unit Settles Claims of Pushing Drugs With Pricey Dinners (NASDAQ:SLXP) www.bloomberg.com - June 9 at 4:38 PM
	U.S. joins whistleblower lawsuit against Valeant's Salix unit (NASDAQ:SLXP) finance.yahoo.com - June 9 at 3:58 PM
	Valeant pays $47M to settle 2013 DOJ investigation into legacy Salix drugs (NASDAQ:SLXP) www.bizjournals.com - June 8 at 12:35 PM
	Biotech: 2 Attractive Buyout Targets For Under $7 A Share - Seeking Alpha (NASDAQ:SLXP) seekingalpha.com - May 26 at 1:11 PM
	Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Broker Price Targets For The Coming Week - Share Trading News (NASDAQ:SLXP) www.sharetrading.news - May 16 at 10:42 AM
	Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Latest Broker Views - Risers & Fallers (NASDAQ:SLXP) www.risersandfallers.com - April 22 at 6:24 PM
	Biomerica - Growing Revenue, Solid Balance Sheet And Potentially Significant Upside From IBS Test - Seeking Alpha (NASDAQ:SLXP) seekingalpha.com - April 19 at 6:31 PM
	Recently Changed Price Targets On Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Risers & Fallers (NASDAQ:SLXP) www.risersandfallers.com - April 12 at 11:30 PM
	Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Latest Broker Coverage - Risers & Fallers (NASDAQ:SLXP) www.risersandfallers.com - April 8 at 6:29 PM
	Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Analyst Review - Risers & Fallers (NASDAQ:SLXP) www.risersandfallers.com - April 7 at 6:36 PM
	Report: Valeant cutting Addyi sales force (NASDAQ:SLXP) www.bizjournals.com - April 5 at 4:30 PM
	Latest Analyst Ratings For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Share Trading News (NASDAQ:SLXP) www.sharetrading.news - April 4 at 6:17 PM
	Next Weeks Broker Price Targets For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Share Trading News (NASDAQ:SLXP) www.sharetrading.news - April 3 at 5:47 PM
	This Weeks Broker Price Targets For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Share Trading News (NASDAQ:SLXP) www.sharetrading.news - March 28 at 10:53 PM
	Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Broker Updates - Risers & Fallers (NASDAQ:SLXP) www.risersandfallers.com - March 23 at 11:02 PM
	New Broker Ratings For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - FTSE News (NASDAQ:SLXP) www.ftsenews.co.uk - March 22 at 5:58 PM
	Atlantic Healthcare closes $24 million financing with founders of Salix Pharmaceuticals and Clinigen Group, and LDC - Business Wire (press release) (NASDAQ:SLXP) www.businesswire.com - March 21 at 8:59 AM
	BMO Still Believes Valeant Is Undervalued - Benzinga (NASDAQ:SLXP) www.benzinga.com - March 17 at 6:12 PM
	Revenue from Salix drug lower than Valeant expected (NASDAQ:SLXP) www.bizjournals.com - March 15 at 4:55 PM
	Valeant missed huge on its 'billion dollar' savior drug — that should raise a big red flag (NASDAQ:SLXP) finance.yahoo.com - March 15 at 12:36 PM
	How Salix/Sprout affected Valeant's earnings (NASDAQ:SLXP) www.bizjournals.com - March 15 at 10:25 AM
	Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Updated Price Targets - Share Trading News (NASDAQ:SLXP) www.sharetrading.news - March 7 at 11:08 PM
	Valeant Says It's Under Investigation by SEC, Shares Plunge (NASDAQ:SLXP) www.bloomberg.com - February 29 at 3:39 PM
	Where Salix fits in Valeant’s earnings restatement (NASDAQ:SLXP) www.bizjournals.com - February 23 at 5:35 PM
	Valeant Has Risk Of New Undisclosed SEC Probe, Report Says (NASDAQ:SLXP) finance.yahoo.com - February 23 at 9:07 AM
	Price Target Update On Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Risers & Fallers (NASDAQ:SLXP) www.risersandfallers.com - February 18 at 9:44 AM
	SEC Investigating Ex-Salix Executives Over Misleading Investors (NASDAQ:SLXP) feeds.benzinga.com - February 10 at 12:33 PM
	SEC investigating former Salix Pharma execs, Reuters reports (NASDAQ:SLXP) www.bizjournals.com - February 9 at 6:15 PM
	SEC probes former Salix CEO, CFO over investor disclosure-source (NASDAQ:SLXP) feeds.reuters.com - February 9 at 3:23 PM
	Recent Broker Updates On Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Risers & Fallers (NASDAQ:SLXP) www.risersandfallers.com - February 8 at 4:33 PM
	Valeant Accused of Hiding Cold Drug Study Results Proving Drug Was No More Effective than a Placebo - PharmaLive (press release) (subscription) (NASDAQ:SLXP) www.pharmalive.com - February 3 at 9:11 AM
	Analyst Coverage Updates - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Risers & Fallers (NASDAQ:SLXP) www.risersandfallers.com - January 29 at 9:17 AM
	Pershing Square's Bill Ackman Writes Letter of Apology to Investors, Regrets Investing so Heavily into Valeant - PharmaLive (press release) (subscription) (NASDAQ:SLXP) www.pharmalive.com - January 28 at 4:09 PM